Clinical trials: Staphylococcus Aureus Infections
Infections, Bacterial
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy…
- Trial name
- NCT00539994
- Testing
- retapamulin
- Where
- 4 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Staphylococcal Infections
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
- Trial name
- NCT01324440
- Testing
- V710 (30 µg) with MAA, V710 (30 µg) without MAA
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers, Anti-Bacterial Agents
A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
To evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of N-Rephasin® SAL200 following single and multiple ascending doses in healthy male volunteers after continuous intravenous infusion over 60 minutes.
- Conditions
- Healthy Volunteers, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
- Trial name
- NCT03446053
- Testing
- N-Rephasin® SAL200
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Staphylococcus Aureus
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body.
- Trial name
- NCT01011335
- Testing
- Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcal Infection
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
This study will assess the nasal eradication of SA in healthy subjects following treatment with mupirocin 2% (Bactroban 2% Nasal Ointment) twice daily for 5 days, by means of a broth enriched culture microbial assay.
- Trial name
- NCT02284555
- Testing
- Mupirocin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Autosomal-dominant Hyper-IgE Syndrome
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Background: AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly Staph and Candida infections.
- Trial name
- NCT02996448
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
S. Aureus Screening and Decolonization
Staphylococcus aureus (SA) healthcare-associated infections (HAI) cause significant morbidity and mortality. SA causes 15% of all HAI and 30% of surgical site infections (SSIs).
- Trial name
- NCT02182115
- Testing
- antiseptic bundle, standard of care
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Hand Hygiene, Health Care Associated Infection
Building an Optimal Hand Hygiene Bundle
Hand hygiene is the single most effective practice in preventing the spread of hospital-acquired infections. Despite the strength of the evidence, hospital staff continue to sanitize their hands less than half of the time…
- Conditions
- Hand Hygiene, Health Care Associated Infection, Compliance
- Trial name
- NCT02223455
- Testing
- Hand Hygiene Signs
- Where
- 10 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Staphylococcal Infections
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to <86 years.
- Trial name
- NCT02492958
- Testing
- Staphylococcus aureus 4-antigen vaccine
- Where
- 2 sites in Japan
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Infection, Abscess
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
- Conditions
- Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
- Trial name
- NCT00352612
- Testing
- clindamycin, cephalexin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aaron Chen
Nasal Carriers of Staphylococcus Aureus
Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current…
- Trial name
- NCT00997139
- Testing
- Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Infectious Disease
Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
The purpose of this study is to determine the extent to which bacterial growth in the nostrils by S. aureus, a common bacteria that is found in hospital environment, can be reduced by NOZIN® Nasal Sanitizer® antiseptic nasal…
- Trial name
- NCT01861457
- Testing
- Nozin® Nasal Sanitizer®
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Staphylococcus Aureus, Health Care Associated Infection
Reducing Perioperative S. Aureus Transmission
The purpose of this study is to prevent the spread of S. aureus, a dangerous bacterium, within the operating room and between patients undergoing surgery.
- Conditions
- Staphylococcus Aureus, Health Care Associated Infection, Health Care Worker Patient Transmission
- Trial name
- NCT03638947
- Testing
- Swab and decolonization using povidone-iodine cleansing
- Where
- United States
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- Randy Loftus
Healthy Volunteers, Anti-Bacterial Agents
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
The Objectives of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single dose of N-Rephasin® SAL200 in healthy male subjects.
- Conditions
- Healthy Volunteers, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus Aureus
- Trial name
- NCT01855048
- Testing
- N-Rephasin® SAL200
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Abscess
Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures.
- Trial name
- NCT00829686
- Testing
- Septra
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- 59th Medical Wing
Staphylococcal Infection
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects.
- Trial name
- NCT00735839
- Testing
- V710
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Soft Tissue
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
The study evaluates the safety, immunogenicity, and efficacy of the GSK S. aureus candidate vaccine (GSK3878858A) when administered to two groups: healthy adults (dose-escalation phase) and adults aged 18 to 64 years with a…
- Trial name
- NCT04420221
- Testing
- Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
This study is being performed to evaluate a single 60 Mcg dose of lyophilized formulation of Merck Staphylococcus aureus vaccine (V710) in healthy subjects.
- Trial name
- NCT00822757
- Testing
- Comparator: V710
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC